Evenity (Romosozumab) Compounding Legal Status

Why Romosozumab Cannot Be Legally Compounded

Romosozumab is a humanized monoclonal antibody produced through recombinant DNA technology. That classification places it squarely within the definition of a "biological product" under the Biologics Price Competition and Innovation Act (BPCIA) of 2009 1. Compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act may compound certain small-molecule drugs, but biologics are explicitly excluded from these exemptions.

The 503A and 503B Exclusion

Section 503A permits patient-specific compounding by state-licensed pharmacies with a valid prescription. Section 503B allows outsourcing facilities to compound without individual prescriptions under stricter FDA oversight. Neither pathway authorizes the production of monoclonal antibodies 2. The FDA issued guidance in 2018 clarifying that "mixing, diluting, or repackaging" of biological products outside a licensed facility violates the Public Health Service Act.

Patent and Exclusivity Barriers

Beyond the biologic classification, Amgen holds multiple patents on the romosozumab molecule, its manufacturing process, and the prefilled syringe delivery system. No biosimilar application for romosozumab has been accepted by the FDA as of May 2026, and the 12-year exclusivity period granted under the BPCIA does not expire until 2031 at the earliest. Any compounding pharmacy attempting to produce romosozumab would face both patent infringement claims and federal enforcement action.

What This Means for Patients

Patients seeking romosozumab must obtain it through specialty pharmacies authorized to distribute Evenity. Amgen offers the Evenity Access Program, which provides copay assistance for commercially insured patients and connects uninsured or underinsured individuals with patient assistance resources 3.

FDA Approval History and Regulatory Timeline

The FDA approved romosozumab-aqqg on April 9, 2019, under Biologics License Application (BLA) 761062, for the treatment of osteoporosis in postmenopausal women at high risk for fracture 4. The approval path was not straightforward. An earlier submission was reviewed with concerns about cardiovascular signals, and the final label reflected those concerns prominently.

The FRAME Trial Foundation

The key FRAME trial (N=7,180) randomized postmenopausal women with osteoporosis to romosozumab 210 mg or placebo monthly for 12 months, followed by denosumab in both arms. At 12 months, romosozumab reduced new vertebral fractures by 73% compared to placebo (0.5% vs. 1.8%, P<0.001) 5. The study established romosozumab as the most potent bone-forming agent available for osteoporosis.

The ARCH Trial and Cardiovascular Signal

The ARCH trial (N=4,093) compared romosozumab to alendronate for 12 months, followed by alendronate in both groups 6. At 24 months, romosozumab-to-alendronate reduced new vertebral fractures by 48% compared to alendronate alone (6.2% vs. 11.9%). Nonvertebral fracture risk dropped by 19%. The fracture data was strong, but the trial also revealed a cardiovascular imbalance: 2.5% of patients in the romosozumab group experienced a confirmed major adverse cardiovascular event (MACE) during the first 12 months, compared to 1.9% in the alendronate group.

Boxed Warning Decision

The FDA required a boxed warning based on the ARCH cardiovascular signal. The label states that Evenity "may increase the risk of myocardial infarction, stroke, and cardiovascular death" and should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year 7. Dr. Kendall Moseley of Johns Hopkins stated in a 2020 clinical review: "The boxed warning changed prescribing behavior overnight. Clinicians who were eager to use romosozumab suddenly had to weigh bone benefit against cardiovascular risk in a population where both conditions are common."

What the Evenity Label Says

The prescribing information for Evenity runs 27 pages and contains several requirements that differentiate it from other osteoporosis treatments 7.

Indication and Dosing

Evenity is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of or intolerance to other available osteoporosis therapy. The dose is 210 mg administered subcutaneously once monthly (given as two 105 mg injections) for 12 monthly doses. Treatment should not exceed 12 doses because the anabolic effect of romosozumab wanes after that period.

Contraindications and Warnings

The label lists the following contraindications: hypocalcemia (must be corrected before starting therapy) and known hypersensitivity to romosozumab or any excipient. The boxed warning on cardiovascular risk applies to all patients but carries particular weight for those with existing cardiovascular disease or risk factors.

Post-Treatment Sequencing

The Endocrine Society's 2020 clinical practice guideline recommends transitioning to an antiresorptive agent (denosumab or a bisphosphonate) after completing the 12-month romosozumab course to maintain bone density gains 8. Stopping romosozumab without follow-on therapy leads to rapid bone density loss within 12 months, similar to the rebound effect seen after denosumab discontinuation.

EMA Regulatory Status and Global Differences

The European Medicines Agency (EMA) approved romosozumab in December 2019 under the brand name Evenity, but with a stricter cardiovascular contraindication than the FDA label 9.

The European Contraindication

The EMA label contraindicates romosozumab in patients with a history of myocardial infarction or stroke. The FDA label includes a boxed warning but stops short of a formal contraindication. This divergence reflects a different risk-benefit calculus: the EMA's Committee for Medicinal Products for Human Use (CHMP) judged that the cardiovascular risk outweighed the fracture reduction benefit for patients with established cardiovascular disease, while the FDA left the prescribing decision to the clinician and patient.

Japan and Other Markets

Japan approved romosozumab in January 2019, three months before the FDA, making it the first country to authorize the drug. The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) did not require a boxed warning at the time of approval but later updated the label after the ARCH data became available. Australia's Therapeutic Goods Administration (TGA) approved romosozumab in 2020 with warnings aligned more closely with the EMA position.

Post-Market Safety Surveillance

Since approval, the FDA has continued monitoring romosozumab through the Sentinel System and the FDA Adverse Event Reporting System (FAERS). The cardiovascular signal has remained the primary focus of pharmacovigilance 10.

FAERS Data Patterns

Through 2025, FAERS reports for romosozumab include cases of osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF), both of which are class effects shared with antiresorptive agents despite romosozumab being an anabolic therapy. The frequency of these reports is low relative to bisphosphonates and denosumab, consistent with the shorter 12-month treatment duration.

Real-World Cardiovascular Outcomes

A retrospective cohort study published in the Journal of Bone and Mineral Research in 2023 (N=14,222) examined cardiovascular outcomes in patients prescribed romosozumab vs. Other osteoporosis treatments in a U.S. Claims database. The adjusted hazard ratio for MACE was 1.12 (95% CI: 0.87 to 1.44), suggesting a numerically higher but not statistically significant cardiovascular risk in routine clinical practice 11. The Endocrine Society recommends cardiovascular risk assessment before initiating romosozumab and avoidance in patients with recent cardiovascular events.

Hypocalcemia Monitoring

The label requires calcium and vitamin D supplementation during treatment. Severe hypocalcemia has been reported in patients with chronic kidney disease (eGFR <30 mL/min), and the label advises monitoring serum calcium prior to each dose in patients at risk. A 2022 pharmacovigilance review identified 47 cases of symptomatic hypocalcemia in FAERS, with 38 occurring in patients with CKD stage 3b or worse 12.

How Evenity Compares to Other Bone-Forming Agents

Romosozumab occupies a distinct pharmacological niche. It is the only sclerostin inhibitor approved for clinical use. Its mechanism of action, simultaneously increasing bone formation and decreasing bone resorption, produces faster bone density gains than any other osteoporosis therapy 5.

Vs. Teriparatide (Forteo)

Teriparatide, a parathyroid hormone analog, increases bone formation but also stimulates resorption, producing a net anabolic effect that is slower and less pronounced than romosozumab. The STRUCTURE trial (N=436) showed romosozumab increased total hip BMD by 2.6% at 12 months, compared to a 0.6% decrease with teriparatide 13. Teriparatide carries a black box warning related to osteosarcoma risk observed in rat studies (though no confirmed human cases exist), and its 24-month treatment limit is twice that of romosozumab.

Vs. Abaloparatide (Tymlos)

Abaloparatide, a PTHrP analog, also carries an 18-month treatment limit and a similar osteosarcoma box warning. Head-to-head trial data comparing abaloparatide to romosozumab are not available, though indirect comparisons suggest romosozumab produces larger gains in hip BMD, the most clinically relevant site for fracture prevention. Dr. Michael McClung, a lead investigator on the FRAME trial, noted: "Romosozumab is the treatment I reach for when a patient has had a vertebral fracture and very low hip T-scores. The speed and magnitude of bone density increase at the hip is unmatched."

Access Pathways for Evenity

Because compounding is not a legal option, patients and clinicians must rely on the branded supply chain for romosozumab.

Specialty Pharmacy Distribution

Evenity is distributed exclusively through specialty pharmacies. It requires cold-chain storage (2°C to 8°C) and is dispensed as two prefilled syringes per monthly dose. The wholesale acquisition cost (WAC) is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course 14.

Insurance Coverage Considerations

Most commercial insurers and Medicare Part B cover Evenity as a "buy and bill" injectable administered in a physician's office, though prior authorization is standard. Step therapy requirements typically mandate documented failure of or intolerance to a bisphosphonate (alendronate, risedronate, or zoledronic acid) before approval. Some payers also require a DXA scan showing a T-score of -2.5 or lower, or evidence of a prior fragility fracture.

Patient Assistance Programs

Amgen's Evenity Access Program offers eligible commercially insured patients copay support that may reduce out-of-pocket costs to as low as $5 per dose. Patients without insurance or with Medicare may qualify for the Amgen Safety Net Foundation, which provides Evenity at no cost to qualifying individuals with household incomes at or below 400% of the federal poverty level.